搜尋結果
Another Approach To Checkpoint Inhibitors: Targeting Receptors
Forbes· 6 日前An alternative to PD-1 targeting cancer therapies, PD-L1 checkpoint inhibitors boost antitumor ...
Opinion | An Alzheimer’s Advance, Not a Cure-All
The Wall Street Journal· 6 日前Donanemab promises progress. The FDA shouldn’t hold out for perfection.